R G Fariello

Summary

Publications

  1. ncbi request reprint Improvement of motor function in early Parkinson disease by safinamide
    F Stocchi
    Department of Neuroscience and IRCCS Neuromed Pozzilli IS, Disorders Centre, Department of Neuroscience, Universita G D Annunzio, Chieti Pescara, Pescara, Italy
    Neurology 63:746-8. 2004
  2. ncbi request reprint Safinamide: from molecular targets to a new anti-Parkinson drug
    C Caccia
    Newron Pharmaceuticals SpA, Bresso, MI, Italy
    Neurology 67:S18-23. 2006
  3. ncbi request reprint Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain
    O Veneroni
    Newron Pharmaceuticals S p A Research and Development, Gerenzano, Varese, Italy
    Pain 102:17-25. 2003
  4. ncbi request reprint Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
    F Stocchi
    IRCCS San Raffaele Pisana, Rome, Italy
    Neurology 67:S24-9. 2006
  5. ncbi request reprint A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease
    L Zecca
    Institute of Biomedical Technologies Italian Research Council, Segrate, Milano, Italy
    Neurology 67:S8-11. 2006

Detail Information

Publications5

  1. ncbi request reprint Improvement of motor function in early Parkinson disease by safinamide
    F Stocchi
    Department of Neuroscience and IRCCS Neuromed Pozzilli IS, Disorders Centre, Department of Neuroscience, Universita G D Annunzio, Chieti Pescara, Pescara, Italy
    Neurology 63:746-8. 2004
    ..1% responders, mean 4.7-point motor score decrease; p > or = 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses...
  2. ncbi request reprint Safinamide: from molecular targets to a new anti-Parkinson drug
    C Caccia
    Newron Pharmaceuticals SpA, Bresso, MI, Italy
    Neurology 67:S18-23. 2006
    ..Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential...
  3. ncbi request reprint Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain
    O Veneroni
    Newron Pharmaceuticals S p A Research and Development, Gerenzano, Varese, Italy
    Pain 102:17-25. 2003
    ..These results indicate that NW-1029 has anti-nociceptive properties in models of inflammatory and neuropathic pain...
  4. ncbi request reprint Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
    F Stocchi
    IRCCS San Raffaele Pisana, Rome, Italy
    Neurology 67:S24-9. 2006
    ..These hypotheses are under investigation and will pursue confirmation in controlled clinical trials...
  5. ncbi request reprint A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease
    L Zecca
    Institute of Biomedical Technologies Italian Research Council, Segrate, Milano, Italy
    Neurology 67:S8-11. 2006
    ..Neuromelanin appears to be a suitable target for devising chemical agents that might modify the course of these diseases...